![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANKRD11 |
Gene summary for ANKRD11 |
![]() |
Gene information | Species | Human | Gene symbol | ANKRD11 | Gene ID | 29123 |
Gene name | ankyrin repeat domain 11 | |
Gene Alias | ANCO-1 | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q6UB99 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29123 | ANKRD11 | CA_HPV_1 | Human | Cervix | CC | 8.81e-05 | 4.37e-02 | 0.0264 |
29123 | ANKRD11 | CA_HPV_2 | Human | Cervix | CC | 8.23e-10 | 4.82e-01 | 0.0391 |
29123 | ANKRD11 | CCI_1 | Human | Cervix | CC | 1.21e-14 | 1.28e+00 | 0.528 |
29123 | ANKRD11 | CCI_2 | Human | Cervix | CC | 1.78e-14 | 1.52e+00 | 0.5249 |
29123 | ANKRD11 | CCI_3 | Human | Cervix | CC | 3.94e-22 | 1.57e+00 | 0.516 |
29123 | ANKRD11 | L1 | Human | Cervix | CC | 4.49e-03 | -2.18e-01 | 0.0802 |
29123 | ANKRD11 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.24e-29 | -6.05e-01 | 0.0155 |
29123 | ANKRD11 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.44e-03 | -5.35e-01 | 0.0216 |
29123 | ANKRD11 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.24e-04 | -3.11e-01 | -0.0811 |
29123 | ANKRD11 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.49e-02 | -3.07e-01 | -0.2196 |
29123 | ANKRD11 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.54e-06 | -3.34e-01 | -0.1462 |
29123 | ANKRD11 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.40e-03 | -5.08e-01 | 0.0588 |
29123 | ANKRD11 | F007 | Human | Colorectum | FAP | 4.01e-07 | 1.43e-01 | 0.1176 |
29123 | ANKRD11 | A002-C-010 | Human | Colorectum | FAP | 1.32e-03 | -1.73e-01 | 0.242 |
29123 | ANKRD11 | A001-C-207 | Human | Colorectum | FAP | 2.87e-03 | -6.65e-02 | 0.1278 |
29123 | ANKRD11 | A015-C-203 | Human | Colorectum | FAP | 2.75e-34 | -4.67e-02 | -0.1294 |
29123 | ANKRD11 | A015-C-204 | Human | Colorectum | FAP | 1.98e-06 | 5.35e-02 | -0.0228 |
29123 | ANKRD11 | A014-C-040 | Human | Colorectum | FAP | 1.81e-07 | 6.63e-02 | -0.1184 |
29123 | ANKRD11 | A002-C-201 | Human | Colorectum | FAP | 2.68e-15 | -5.93e-02 | 0.0324 |
29123 | ANKRD11 | A001-C-119 | Human | Colorectum | FAP | 9.47e-24 | 3.44e-01 | -0.1557 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048705 | Colorectum | CRC | skeletal system morphogenesis | 37/2078 | 220/18723 | 6.58e-03 | 4.71e-02 | 37 |
GO:00603242 | Esophagus | ESCC | face development | 34/8552 | 44/18723 | 1.90e-05 | 1.67e-04 | 34 |
GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
GO:00603253 | Esophagus | ESCC | face morphogenesis | 21/8552 | 28/18723 | 1.57e-03 | 7.33e-03 | 21 |
GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
GO:00603232 | Esophagus | ESCC | head morphogenesis | 22/8552 | 32/18723 | 7.12e-03 | 2.58e-02 | 22 |
GO:0060325 | Liver | NAFLD | face morphogenesis | 8/1882 | 28/18723 | 5.07e-03 | 3.96e-02 | 8 |
GO:0060324 | Oral cavity | OSCC | face development | 28/7305 | 44/18723 | 8.15e-04 | 4.35e-03 | 28 |
GO:00603252 | Oral cavity | OSCC | face morphogenesis | 18/7305 | 28/18723 | 5.96e-03 | 2.27e-02 | 18 |
GO:0060323 | Oral cavity | OSCC | head morphogenesis | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
GO:00603241 | Oral cavity | NEOLP | face development | 16/2005 | 44/18723 | 6.27e-06 | 1.26e-04 | 16 |
GO:00603231 | Oral cavity | NEOLP | head morphogenesis | 12/2005 | 32/18723 | 6.38e-05 | 8.40e-04 | 12 |
GO:00603251 | Oral cavity | NEOLP | face morphogenesis | 11/2005 | 28/18723 | 7.84e-05 | 1.00e-03 | 11 |
GO:0010171 | Oral cavity | NEOLP | body morphogenesis | 14/2005 | 43/18723 | 9.66e-05 | 1.18e-03 | 14 |
GO:00487051 | Oral cavity | NEOLP | skeletal system morphogenesis | 36/2005 | 220/18723 | 6.47e-03 | 3.33e-02 | 36 |
GO:00603254 | Skin | AK | face morphogenesis | 10/1910 | 28/18723 | 2.78e-04 | 2.94e-03 | 10 |
GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00603233 | Skin | AK | head morphogenesis | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:00603243 | Skin | AK | face development | 12/1910 | 44/18723 | 1.16e-03 | 8.88e-03 | 12 |
GO:00603244 | Thyroid | PTC | face development | 24/5968 | 44/18723 | 1.52e-03 | 8.49e-03 | 24 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD11 | SNV | Missense_Mutation | c.7735C>T | p.Arg2579Cys | p.R2579C | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANKRD11 | SNV | Missense_Mutation | novel | c.7258G>A | p.Asp2420Asn | p.D2420N | Q6UB99 | protein_coding | tolerated(0.22) | benign(0.184) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD11 | SNV | Missense_Mutation | novel | c.1200G>T | p.Lys400Asn | p.K400N | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD11 | SNV | Missense_Mutation | c.4871C>T | p.Ala1624Val | p.A1624V | Q6UB99 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANKRD11 | SNV | Missense_Mutation | novel | c.7379N>T | p.Pro2460Leu | p.P2460L | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ANKRD11 | SNV | Missense_Mutation | rs761377016 | c.5369N>T | p.Ser1790Leu | p.S1790L | Q6UB99 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ANKRD11 | SNV | Missense_Mutation | rs763414376 | c.1726N>A | p.Glu576Lys | p.E576K | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ANKRD11 | SNV | Missense_Mutation | novel | c.5759C>T | p.Thr1920Met | p.T1920M | Q6UB99 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.837) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD11 | SNV | Missense_Mutation | novel | c.4582G>A | p.Ala1528Thr | p.A1528T | Q6UB99 | protein_coding | tolerated(0.91) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD11 | SNV | Missense_Mutation | novel | c.589A>G | p.Lys197Glu | p.K197E | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |